228 related articles for article (PubMed ID: 20837537)
1. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events.
Liu JY; Li N; Yang J; Li N; Qiu H; Ai D; Chiamvimonvat N; Zhu Y; Hammock BD
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):17017-22. PubMed ID: 20837537
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.
Zhang Y; Hoda MN; Zheng X; Li W; Luo P; Maddipati KR; Seki T; Ergul A; Wang MH
Am J Physiol Regul Integr Comp Physiol; 2014 Sep; 307(6):R693-703. PubMed ID: 24990856
[TBL] [Abstract][Full Text] [Related]
3. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
[TBL] [Abstract][Full Text] [Related]
4. The patient's perspective on the recall of Vioxx.
Hawker GA; Katz JN; Solomon DH
J Rheumatol; 2006 Jun; 33(6):1082-8. PubMed ID: 16755654
[TBL] [Abstract][Full Text] [Related]
5. Disruption of elastic lamellae in aorta and dysfunction of vaso-regulation by rofecoxib in rats.
Miyajima A; Okamoto M; Muto T; Hirota T
J Toxicol Sci; 2013; 38(5):719-29. PubMed ID: 24025789
[TBL] [Abstract][Full Text] [Related]
6. Persistence of cardiovascular risk after rofecoxib discontinuation.
Ross JS; Madigan D; Konstam MA; Egilman DS; Krumholz HM
Arch Intern Med; 2010 Dec; 170(22):2035-6. PubMed ID: 21149763
[No Abstract] [Full Text] [Related]
7. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550
[TBL] [Abstract][Full Text] [Related]
8. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
Mühlbauer B; Timm J
Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669
[No Abstract] [Full Text] [Related]
9. Introduction - The coxib controversies.
Rainsford KD
Inflammopharmacology; 2005; 13(4):331-41. PubMed ID: 16354388
[TBL] [Abstract][Full Text] [Related]
10. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
Sukel MP; van der Linden MW; Chen C; Erkens JA; Herings RM
Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):9-19. PubMed ID: 17963198
[TBL] [Abstract][Full Text] [Related]
11. [How many harmed by rofecoxib in Germany?].
Scharnetzky E; Andersohn F; Schill W; Garbe E; Pigeot I
Med Klin (Munich); 2006 Aug; 101(8):675-6; author reply 678-9. PubMed ID: 17051670
[No Abstract] [Full Text] [Related]
12. Rofecoxib-induced hepatotoxicity: a forgotten complication of the coxibs.
Yan B; Leung Y; Urbanski SJ; Myers RP
Can J Gastroenterol; 2006 May; 20(5):351-5. PubMed ID: 16691302
[TBL] [Abstract][Full Text] [Related]
13. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
[TBL] [Abstract][Full Text] [Related]
14. Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.
Gudbjornsson B; Thorsteinsson SB; Sigvaldason H; Einarsdottir R; Johannsson M; Zoega H; Halldorsson M; Thorgeirsson G
Eur J Clin Pharmacol; 2010 Jun; 66(6):619-25. PubMed ID: 20157701
[TBL] [Abstract][Full Text] [Related]
15. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
[TBL] [Abstract][Full Text] [Related]
16. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
Lévesque LE; Brophy JM; Zhang B
CMAJ; 2006 May; 174(11):1563-9. PubMed ID: 16670396
[TBL] [Abstract][Full Text] [Related]
17. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
18. [What do we know about the cardiovascular toxicity of the NSAIDs?].
Sibilia J; Deray G; Montalescot G
Presse Med; 2006 Sep; 35(9 Spec No 1):1S11-23. PubMed ID: 17078591
[TBL] [Abstract][Full Text] [Related]
19. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Hsiao FY; Tsai YW; Huang WF
Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
[TBL] [Abstract][Full Text] [Related]
20. Cerebrovascular events after discontinuation of rofecoxib treatment.
Andersohn F
Cardiovasc Drugs Ther; 2007 Apr; 21(2):77-9. PubMed ID: 17404824
[No Abstract] [Full Text] [Related]
[Next] [New Search]
